Novartis races into clinic with swine flu vax

Novartis has begun testing a new swine flu vaccine in a clinical trial, but says it expects to get the jab on the market long before the study winds up a year from now. Sanofi-Pasteur, meanwhile, expects to launch human trials in a matter of days. Novartis is planning to use egg-based production methods for half of its new flu vaccine, with cell-based technology used to manufacture the other half. And it also expects to test vaccines with and without an adjuvant. While the WHO has recommended the use of adjuvants to extend the reach of global supplies, the U.S. has yet to follow Europe's lead on the use of a booster--though that may change this fall. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.